In short
Copanlisib Dihydrochloride, also known as Aliqopa, is an investigational drug being studied in various clinical trials for its potential in treating different types of cancer. This article explores the ongoing research into Copanlisib Dihydrochloride's efficacy and safety in combination with other treatments for conditions such as lymphomas, breast cancer, and other advanced solid tumors.
At a glance
- Drug Name
- Copanlisib Dihydrochloride (also known as Aliqopa, BAY 80-6946 Dihydrochloride)
- Mechanism of Action
- PI3K inhibitor, blocks enzymes needed for cancer cell growth
- Administration
- Intravenous (IV) infusion, typically over 1 hour
- Cancer Types Studied
- Mantle cell lymphoma, diffuse large B-cell lymphoma, breast cancer, ovarian cancer, advanced solid tumors
- Combination Therapies
- Studied with venetoclax, nivolumab, ipilimumab, olaparib, abemaciclib, fulvestrant
- Key Outcomes Measured
- Progression-free survival, overall response rate, overall survival, safety profile
- Common Side Effects
- High blood sugar, high blood pressure, diarrhea, decreased white blood cell counts
- Trial Phases
- Phase I, II, and III studies ongoing
- Patient Populations
- Often focuses on relapsed or refractory cancers, or those with specific genetic mutations
- Biomarker Studies
- Investigations into PI3K pathway mutations, PTEN loss, and other potential predictive markers
What is Copanlisib Dihydrochloride?
Copanlisib Dihydrochloride, also known as Copanlisib, is an investigational anti-cancer drug that belongs to a class of medications called PI3K inhibitors. It is being studied for its potential to treat various types of cancers, particularly those that have not responded well to other treatments or have come back after initial treatment.
This drug is also known by several other names, including: Aliqopa BAY 80-6946 Dihydrochloride BAY-80-6946 Dihydrochloride 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2) These alternative names may be used in medical literature or by healthcare providers.
How Does Copanlisib Dihydrochloride Work?
Copanlisib Dihydrochloride works by blocking certain enzymes in cancer cells that are needed for their growth. Specifically, it targets proteins called PI3K (phosphatidylinositol-3-kinase), which are involved in cell growth and survival. By inhibiting these proteins, Copanlisib may help to stop or slow down the growth of cancer cells.
This mechanism of action makes Copanlisib particularly interesting for cancers that have mutations in the PI3K pathway, as these cancers may be more dependent on this pathway for their growth and survival.
What Conditions Does Copanlisib Dihydrochloride Treat?
Copanlisib Dihydrochloride is being studied for the treatment of several types of cancer, including:
- Lymphomas: Particularly non-Hodgkin lymphoma and mantle cell lymphoma that have come back or are resistant to other treatments
- Solid tumors: Including advanced or metastatic cancers that have specific genetic mutations, such as PIK3CA mutations or PTEN loss
- Breast cancer: Especially hormone receptor-positive, HER2-negative metastatic breast cancer
- Ovarian cancer: Particularly in cases that are resistant to platinum-based chemotherapy
It's important to note that Copanlisib is still being studied for these conditions, and its effectiveness may vary depending on the specific type and stage of cancer.
How is Copanlisib Dihydrochloride Administered?
Copanlisib Dihydrochloride is typically given as an intravenous (IV) infusion, which means it's delivered directly into the bloodstream through a vein. The specific dosing schedule can vary depending on the study or treatment plan, but common schedules include:
- Once weekly for three weeks, followed by one week off
- On days 1, 8, and 15 of a 28-day cycle
The infusion usually takes about one hour. Your healthcare team will monitor you closely during and after the infusion to watch for any side effects or reactions.
Current Clinical Trials
Copanlisib Dihydrochloride is currently being studied in several clinical trials. These trials are investigating its use:
- In combination with other cancer drugs, such as venetoclax for mantle cell lymphoma
- Together with immunotherapy drugs like nivolumab for various solid tumors
- In combination with hormone therapy and targeted therapy for breast cancer
- As part of a combination therapy for ovarian cancer that has become resistant to other treatments
These trials aim to determine the safety and effectiveness of Copanlisib in different cancer types and in combination with other treatments.
Potential Side Effects
As with any medication, Copanlisib Dihydrochloride can cause side effects. Common side effects observed in clinical trials include:
- High blood sugar levels (hyperglycemia)
- High blood pressure (hypertension)
- Diarrhea
- Decreased white blood cell count, which can increase the risk of infections
- Fatigue
- Nausea
Your healthcare team will monitor you closely for these and other potential side effects. It's important to report any new symptoms or changes in your health to your doctor.
Future Prospects
The ongoing clinical trials are exploring the potential of Copanlisib Dihydrochloride in various cancer types and in combination with other treatments. Researchers are particularly interested in its effectiveness in cancers with specific genetic mutations, such as PIK3CA mutations or PTEN loss.
If these trials show promising results, Copanlisib could become an important treatment option for patients with certain types of cancer, especially those who have not responded well to other treatments. However, more research is needed to fully understand its benefits and risks.